Literature DB >> 21036706

A positive relationship between filamin and VEGF in patients with lung cancer.

Hidetaka Uramoto1, Levent M Akyürek, Takeshi Hanagiri.   

Abstract

Induction of angiogenic responses by multiple factors, a crucial step in tumor growth and metastasis, is not completely understood. Recently, involvement of the cytoskeletal actin-binding proteins in angiogenesis has been suggested as a target for anti-neovascular cancer therapy in vitro. In this study, the expression of filamin A (FLNA) and vascular endothelial growth factor (VEGF) in paraffin-embedded tumor samples from patients with well-characterized lung tumors was immunohistochemically analyzed and compared with clinical variables and survival outcome. A positive expression of FLNA and VEGF was detected in the cytoplasm of tumor cells in 66 (48.2%) and 69 (50.4%) of the 137 patients with lung cancer, respectively (p<0.0001). A significant difference was observed between FLNA expression and VEGF expression. Although our findings do not suggest that the expression of FLNA alone plays an independent prognostic role, the angiogenesis pathway mediated by FLNA appears to be responsible for controlling the growth of lung tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036706

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.

Authors:  Arun K Nalla; Theodore F Williams; Casey P Collins; Dustin T Rae; Grant D Trobridge
Journal:  Mol Carcinog       Date:  2015-10-29       Impact factor: 4.784

Review 2.  Filamin-A expression in laryngeal squamous cell carcinoma and its clinical significance.

Authors:  Abderrahman Ouban
Journal:  Histol Histopathol       Date:  2021-10-22       Impact factor: 2.303

3.  Silencing Filamin A Inhibits the Invasion and Migration of Breast Cancer Cells by Up-regulating 14-3-3σ.

Authors:  Zhi-Min Ji; Li-Li Yang; Juan Ni; San-Peng Xu; Cheng Yang; Pei Duan; Li-Ping Lou; Qiu-Rong Ruan
Journal:  Curr Med Sci       Date:  2018-06-22

4.  Hypoxia-induced and calpain-dependent cleavage of filamin A regulates the hypoxic response.

Authors:  Xiaowei Zheng; Alex-Xianghua Zhou; Pegah Rouhi; Hidetaka Uramoto; Jan Borén; Yihai Cao; Teresa Pereira; Levent M Akyürek; Lorenz Poellinger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

5.  FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway.

Authors:  Mengmeng Cheng; Yannan Jiang; Han Yang; Dongyao Zhao; Longyu Li; Xinyu Liu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 6.  The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it.

Authors:  Rosalinda M Savoy; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2013-11-04       Impact factor: 5.678

7.  Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.

Authors:  Pengxin Zhao; Weiyuan Ma; Zhigang Hu; Leilei Zang; Zhisheng Tian; Kaili Zhang
Journal:  Tumour Biol       Date:  2015-11-07

Review 8.  Filamin A: Insights into its Exact Role in Cancers.

Authors:  Qian-Qian Shao; Tai-Ping Zhang; Wen-Jing Zhao; Zi-Wen Liu; Lei You; Li Zhou; Jun-Chao Guo; Yu-Pei Zhao
Journal:  Pathol Oncol Res       Date:  2015-09-05       Impact factor: 3.201

9.  Cytoskeletal Filamin A Differentially Modulates RNA Polymerase III Gene Transcription in Transformed Cell Lines.

Authors:  Juan Wang; Shasha Zhao; Yun Wei; Ying Zhou; Paul Shore; Wensheng Deng
Journal:  J Biol Chem       Date:  2016-10-13       Impact factor: 5.157

Review 10.  The mechanobiome: a goldmine for cancer therapeutics.

Authors:  Eleana Parajón; Alexandra Surcel; Douglas N Robinson
Journal:  Am J Physiol Cell Physiol       Date:  2020-11-11       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.